LP-184 by Starlight Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

LP-184 is under clinical development by Starlight Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Europe lines up first CRISPR therapy approval

Following FDA approval, Vertex Pharmaceuticals and CRISPR Therapeutics on Friday received a positive recommendation for a conditional approval by a key European medicines panel for

December 16, 2023

Stroke risk rises in patients with sickle cell disease despite established guidelines

The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in Sickle Cell

September 20, 2024

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

February 28, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.